BioNTech SE (BNTX)
One simple reason why BioNTech stock is a raging buy on today's crash
BioNTech (NASDAQ: BNTX) swung to a Q4 loss and guided for “lower-than-expected” full-year revenue on Tuesday. But the stock crashed more than 20%, mostly because its cofounders, Ugur Sahin (CEO) and Ozlem Tureci (CMO), said they would depart to set up a new biotech firm at the end of 2026.
BioNTech co-founders set to launch new mRNA venture as company sharpens oncology focus
BioNTech SE (NASDAQ:BNTX) co-founders Ugur Sahin and Özlem Türeci plan to launch a new independent biotech company focused on next-generation mRNA technologies, the German vaccine developer said on Tuesday, as it intensifies its focus on oncology. BioNTech said it will contribute certain related rights and technologies to the new venture in exchange for a minority stake, with potential milestone payments and royalties.
Scientists behind COVID-19 vaccine will depart BioNTech
The company's co-founders said they are leaving to start a new mRNA-based company.
BioNTech Cofounders to Leave to Form New Company
The company said its cofounders were leaving to form a biotechnology startup focused on developing messenger RNA.
BioNTech: The Market Is Pricing Low Oncology Success
BioNTech SE is transitioning from a COVID-19 vaccine story to a late-stage oncology platform with a robust $17B cash position. At a $27.6B market cap and ~$11B enterprise value, BNTX's pipeline—including Pumitamig, ADCs, and mRNA vaccines—is valued conservatively by the market. Scenario analysis shows downside is cushioned by cash, while upside hinges on pivotal oncology data over the next 12–18 months.
BioNTech (BNTX) Soars 11.8%: Is Further Upside Left in the Stock?
BioNTech (BNTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
BioNTech SE (BNTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
BioNTech SE (BNTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
BioNTech: Maintaining "Strong Buy" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart
BioNTech (BNTX) maintains a "Strong Buy" rating, driven by positive phase 3 data for gotistobart in 2nd-line squamous NSCLC patients. BNTX's gotistobart delivered a 63.1% 12-month OS rate versus 30.3% for docetaxel, reducing risk of death by 54%. Upcoming pivotal phase 3 PRESERVE-003 data in 2026 and expansion into ovarian and prostate cancers offer significant pipeline catalysts.
FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks
A report that vaccine approvals could be set to get stricter is pressuring shares of major vaccine makers.
BioNTech SE (BNTX) Discusses Oncology Innovation Strategy, Combination Therapies and Personalized Cancer Immunotherapies Transcript
BioNTech SE ( BNTX ) Discusses Oncology Innovation Strategy, Combination Therapies and Personalized Cancer Immunotherapies November 11, 2025 9:00 AM EST Company Participants Ugur Sahin - Co-Founder, CEO & Chair of the Management Board Özlem Türeci - Co-Founder, Chief Medical Officer & Member of Management Board Ilhan Celik Michael Wenger Ramón Zapata-Gomez - CFO & Member of Management Board Douglas Maffei - Vice President of Strategy & Investor Relations Annemarie Hanekamp - Chief Commercial Officer & Member of Management Board Conference Call Participants Daina Graybosch - Leerink Partners LLC, Research Division Tazeen Ahmad - BofA Securities, Research Division Jay Lee - Morningstar Inc., Research Division Akash Tewari - Jefferies LLC, Research Division Terence Flynn - Morgan Stanley, Research Division William Maughan - Clear Street LLC., Research Division Jae-Young Park Malcolm Hoffman - BMO Capital Markets Equity Research Asthika Goonewardene - Truist Securities, Inc., Research Division William Zhang Presentation Unknown Executive [Audio Gap] by Annemarie Hanekamp, our Chief Commercial Officer.
BioNTech Q3 Earnings: Plenty Of Cash And Pipeline Potential, But Still A Hold
BioNTech SE shared its Q3 earnings, business updates, and guidance for 2025 earlier today. Its share price is down 1% in trading so far. BNTX maintains a strong cash position, driven by ongoing Comirnaty COVID vaccine sales and significant upfront payments from Bristol-Myers Squibb. BNTX's oncology pipeline, led by pumitamig, is progressing but lacks best-in-class data or approvals, making future revenue potential uncertain.
BioNTech SE (BNTX) Q3 2025 Earnings Call Transcript
BioNTech SE ( BNTX ) Q3 2025 Earnings Call November 3, 2025 8:00 AM EST Company Participants Douglas Maffei Ugur Sahin - Co-Founder, CEO & Chair of the Management Board Özlem Türeci - Co-Founder, Chief Medical Officer & Member of Management Board Ramón Zapata-Gomez - CFO & Member of Management Board Conference Call Participants Tazeen Ahmad - BofA Securities, Research Division Terence Flynn - Morgan Stanley, Research Division Daina Graybosch - Leerink Partners LLC, Research Division Nick Jennings - Goldman Sachs Group, Inc., Research Division Manoj Eradath - Jefferies LLC, Research Division Yaron Werber - TD Cowen, Research Division Mohit Bansal - Wells Fargo Securities, LLC, Research Division Malcolm Hoffman - BMO Capital Markets Equity Research Mario Joshua Chazaro Cortes - Evercore ISI Institutional Equities, Research Division Jay Olson - Oppenheimer & Co. Inc., Research Division Presentation Operator Welcome to BioNTech's Third Quarter 2025 Earnings Call. I will now hand the call over to Doug Maffei, Vice President, Strategy and Investor Relations.
